China Biologics' fibrinogen moves into large Chinese trial
This article was originally published in Scrip
Executive Summary
The recent regulatory approval for a clinical trial programme with China Biologic Products' (CBP) first human fibrinogen preparation is expected to lead to the commercial production and sale of the product in around two years' time.